Trichostatin A and Oncolytic HSV Combination Therapy Shows Enhanced Antitumoral and Antiangiogenic Effects

Overview

Journal Mol Ther

Publisher Cell Press

Specialties Molecular Biology
Pharmacology

Date 2008 Apr 5

PMID 18388912

Citations 46

Authors

Ta-Chiang Liu

Pedro Castelo-Branco

Samuel D Rabkin

Robert L Martuza

Affiliations

Soon will be listed here.

Abstract

Oncolytic herpes simplex viruses (HSVs) possess direct oncolytic and antiangiogenic activities and are promising anticancer agents, but their efficacy, when used as single agents, leaves room for improvement. We investigated whether combination therapy of HSV with histone deacetylase inhibitor trichostatin A (TSA), an agent that also targets cancer cells and tumor vasculature, would result in enhanced efficacy. In vitro, TSA and G47Delta showed strong synergy of action against proliferating endothelial cells, varying degrees of synergistic action against most cancer cell lines, but no effect in quiescent, normal endothelial and prostate epithelial cells. Synergy is dependent on viral replication; however, it is not dependent on the dosing sequence of TSA and G47Delta, viral genetic alterations, infectivity, or replication kinetics of G47Delta. Using an isogenic cell system, we found that a high level of cellular cyclin D1 is also critically important for the interaction. Normal cells with low cyclin D1 levels were not subjected to toxicity by either agent. In tumor cells and proliferating endothelial cells, the combination treatment enhanced the inhibition of cyclin D1 and vascular endothelial growth factor (VEGF). Concurrent systemic TSA and intratumoral G47Delta administration resulted in enhanced antiangiogenesis and enhanced antitumoral efficacy in animal models. Therefore, combination treatment with TSA and oncolytic HSV provides a novel approach to cancer therapy.

Citing Articles

Oncolytic virotherapy against lung cancer: key receptors and signaling pathways of viral entry.

Dong W, Luo Y, He D, Zhang M, Zeng J, Chen Y Front Immunol. 2024; 15:1473288.

PMID: 39430750 PMC: 11486668. DOI: 10.3389/fimmu.2024.1473288.

HRS Facilitates Newcastle Disease Virus Replication in Tumor Cells by Promoting Viral Budding.

Chen Y, Wang C, Hu S, Liu X Int J Mol Sci. 2024; 25(18).

PMID: 39337546 PMC: 11432301. DOI: 10.3390/ijms251810060.

Histone deacetylase inhibitor boosts anticancer potential of fusogenic oncolytic vaccinia virus by enhancing cell-cell fusion.

Nakatake M, Kurosaki H, Nakamura T Cancer Sci. 2023; 115(2):600-610.

PMID: 38037288 PMC: 10859623. DOI: 10.1111/cas.16032.

Oncolytic virotherapy: basic principles, recent advances and future directions.

Lin D, Shen Y, Liang T Signal Transduct Target Ther. 2023; 8(1):156.

PMID: 37041165 PMC: 10090134. DOI: 10.1038/s41392-023-01407-6.

Fusion peptide is superior to co-expressing subunits for arming oncolytic herpes virus with interleukin 12.

Fukuhara H, Sato Y, Hou J, Iwai M, Todo T Commun Med (Lond). 2023; 3(1):40.

PMID: 36966232 PMC: 10039936. DOI: 10.1038/s43856-023-00270-4.

References

Todo T, Martuza R, Rabkin S, Johnson P . Oncolytic herpes simplex virus vector with enhanced MHC class I presentation and tumor cell killing. Proc Natl Acad Sci U S A. 2001; 98(11):6396-401. PMC: 33479. DOI: 10.1073/pnas.101136398. View

Miller C, Danaher R, Jacob R . ICP0 is not required for efficient stress-induced reactivation of herpes simplex virus type 1 from cultured quiescently infected neuronal cells. J Virol. 2006; 80(7):3360-8. PMC: 1440419. DOI: 10.1128/JVI.80.7.3360-3368.2006. View

Vigushin D, Ali S, Pace P, Mirsaidi N, Ito K, Adcock I . Trichostatin A is a histone deacetylase inhibitor with potent antitumor activity against breast cancer in vivo. Clin Cancer Res. 2001; 7(4):971-6. View

He L, Tolentino T, Grayson P, Zhong S, Warrell Jr R, Rifkind R . Histone deacetylase inhibitors induce remission in transgenic models of therapy-resistant acute promyelocytic leukemia. J Clin Invest. 2001; 108(9):1321-30. PMC: 209432. DOI: 10.1172/JCI11537. View

Liu T, Galanis E, Kirn D . Clinical trial results with oncolytic virotherapy: a century of promise, a decade of progress. Nat Clin Pract Oncol. 2007; 4(2):101-17. DOI: 10.1038/ncponc0736. View

Marks P, Rifkind R, Richon V, Breslow R, Miller T, Kelly W . Histone deacetylases and cancer: causes and therapies. Nat Rev Cancer. 2002; 1(3):194-202. DOI: 10.1038/35106079. View

Liu T, Kirn D . Systemic efficacy with oncolytic virus therapeutics: clinical proof-of-concept and future directions. Cancer Res. 2007; 67(2):429-32. DOI: 10.1158/0008-5472.CAN-06-2871. View

Liu T, Zhang T, Fukuhara H, Kuroda T, Todo T, Martuza R . Oncolytic HSV armed with platelet factor 4, an antiangiogenic agent, shows enhanced efficacy. Mol Ther. 2006; 14(6):789-97. DOI: 10.1016/j.ymthe.2006.07.011. View

Yoo J, Kim J, Kwon Y, Kim E, Kim N, Choi H . VEGF-specific short hairpin RNA-expressing oncolytic adenovirus elicits potent inhibition of angiogenesis and tumor growth. Mol Ther. 2007; 15(2):295-302. DOI: 10.1038/sj.mt.6300023. View

10.

Cinatl Jr J, Michaelis M, Hernaiz Driever P, Cinatl J, Hrabeta J, Suhan T . Multimutated herpes simplex virus g207 is a potent inhibitor of angiogenesis. Neoplasia. 2005; 6(6):725-35. PMC: 1531676. DOI: 10.1593/neo.04265. View

11.

Hu J, Colburn N . Histone deacetylase inhibition down-regulates cyclin D1 transcription by inhibiting nuclear factor-kappaB/p65 DNA binding. Mol Cancer Res. 2005; 3(2):100-9. DOI: 10.1158/1541-7786.MCR-04-0070. View

12.

Archer S, Meng S, Shei A, Hodin R . p21(WAF1) is required for butyrate-mediated growth inhibition of human colon cancer cells. Proc Natl Acad Sci U S A. 1998; 95(12):6791-6. PMC: 22637. DOI: 10.1073/pnas.95.12.6791. View

13.

Bieler A, Mantwill K, Dravits T, Bernshausen A, Glockzin G, Kohler-Vargas N . Novel three-pronged strategy to enhance cancer cell killing in glioblastoma cell lines: histone deacetylase inhibitor, chemotherapy, and oncolytic adenovirus dl520. Hum Gene Ther. 2006; 17(1):55-70. DOI: 10.1089/hum.2006.17.55. View

14.

Chen B, Erlanger B . Cell cycle inhibition by an anti-cyclin D1 antibodychemically modified for intracellular delivery. Cancer Lett. 2006; 244(1):71-5. DOI: 10.1016/j.canlet.2005.12.011. View

15.

Kurozumi K, Hardcastle J, Thakur R, Yang M, Christoforidis G, Fulci G . Effect of tumor microenvironment modulation on the efficacy of oncolytic virus therapy. J Natl Cancer Inst. 2007; 99(23):1768-81. DOI: 10.1093/jnci/djm229. View

16.

Magner W, Tomasi T . Apoptotic and necrotic cells induced by different agents vary in their expression of MHC and costimulatory genes. Mol Immunol. 2005; 42(9):1033-42. DOI: 10.1016/j.molimm.2004.09.030. View

17.

Kelly W, Marks P . Drug insight: Histone deacetylase inhibitors--development of the new targeted anticancer agent suberoylanilide hydroxamic acid. Nat Clin Pract Oncol. 2005; 2(3):150-7. DOI: 10.1038/ncponc0106. View

18.

Kitazono M, Goldsmith M, Aikou T, Bates S, Fojo T . Enhanced adenovirus transgene expression in malignant cells treated with the histone deacetylase inhibitor FR901228. Cancer Res. 2001; 61(17):6328-30. View

19.

Kim M, Kwon H, Lee Y, Baek J, Jang J, Lee S . Histone deacetylases induce angiogenesis by negative regulation of tumor suppressor genes. Nat Med. 2001; 7(4):437-43. DOI: 10.1038/86507. View

20.

Minucci S, Pelicci P . Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer. Nat Rev Cancer. 2006; 6(1):38-51. DOI: 10.1038/nrc1779. View